ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.
The nation’s drug shortage crisis continues to affect cancer patients and survivors with 1 in every 10 (10%) reporting impacts to care, a majority of whom have had difficulties finding substitute medications (68%) and cited treatment delays (45%).
Our latest Survivor Views survey sees increases in biomarker testing since the question was last asked three years ago along with reduced cost and coverage barriers in that time. Cancer patients and survivors describe the benefits and overwhelmingly agree biomarker testing gave their providers information that improved their treatment.
ACS and ACS CAN provided comments to the Centers for Medicare and Medicaid Services on the list of Part D drugs selected for the price negotiation program authorized under the Inflation Reduction Act (IRA).
The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) along with partners appreciate the opportunity to comment on the Patient Navigation provisions of CY2024 Medicare Physician Fee Schedule.
Access to care for those who are uninsured not only ensures that serious diseases like cancer can be detected and treated earlier but also often means better patient outcomes and less costs to the individual and the larger health care system.
The American Cancer Society Cancer Action Network (ACS CAN) provided the following statement for the record at the House Energy & Commerce Health Subcommittee Hearing on Legislative Solutions to Bolster Preparedness and Response for all Hazards and Public Health Security Threats on June 13, 2023.
The American Cancer Society Cancer Action Network (ACS CAN) provided the following statement for the record at the House Energy & Commerce Oversight Hearing on Examining the Root Causes of Drug Shortages: Challenges in Pharmaceutical Drug Supply Chains on May 11, 2023.
Our latest survey finds that cancer patients and survivors would be less likely to stay current with preventive care, including recommended cancer screenings, if the provision requiring these services be covered at no cost were repealed. This survey also explores the challenges of limited provider networks and the need for patient navigation.
Biological drugs, commonly referred to as biologics, are a class of drugs that are produced using a living system, such as a microorganism, plant cell, or animal cell. Like all drugs, biologics are regulated by the United States Food and Drug Administration (FDA).
For an individual with specific health care needs – like cancer patients and survivors – the drugs covered by a health plan and corresponding cost sharing for each drug is important information when choosing health insurance. However, to make an informed choice, formulary information must be disclosed to the individual.
This ACS CAN chartbook provides cancer-specific data related to Medicare, including basic information about the program, a discussion of its components, characteristics of enrollees, coverage of services – specifically those related to prevention and screening – program expenditures and enrollees
The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) along with partners appreciate the opportunity to comment on the Patient Navigation provisions of CY2024 Medicare Physician Fee Schedule.
A majority of cancer patients and survivors struggle to afford cancer care and over 80% have had to make financial sacrifices to cover their health care expenses. This survey also reveals ways that affordability concerns can negatively impact care and treatment, and explores issues related to prescription drug coverage and pain management options.
In these comments, ACS CAN strongly supports Congress’ and the Administration’s efforts to protect patients from surprise medical bills and we are encouraged by the important steps this interim final rule takes. Specifically, we applaud the Departments’ proposed policies related to:
High deductible health plans (HDHPs) and health savings accounts (HSAs) are becoming more common in employer-sponsored insurance and the individual and small group markets. These types of plans have risks and features must be implemented carefully so they do not harm cancer patients, survivors or those at risk for cancer.
Cancer patients are particularly vulnerable to spikes in their health care costs because many expensive diagnostic tests and treatments are scheduled within a short period of time, so cancer patients spend their deductible and out-of-pocket maximum quickly. These costs can be difficult to manage over the course of a year, and most monthly budgets simply can’t afford these large bills.
Most patients experience spikes in their health care costs around the time of a cancer diagnosis as they pay their deductible and out-of-pocket maximum. For patients on high deductible plans, this spike can mean bills due for several thousands of dollars within one month.
The U.S. spent approximately $183 billion on cancer-related health care in 2015. This represents a signification portion of the total health care spending in the U.S. And it is expected to keep growing. By 2030 cancer-related health care spending is expected to reach nearly $246 billion.
The Affordable Care Act (ACA) has helped individuals with pre-existing conditions like cancer access comprehensive health insurance and afford their care. But the law is at risk of being dismantled.
This report explores the experiences of cancer patients with their health insurance and financial challenges through interviews with hospital-based financial navigators. The report finds that while the Affordable Care Act has brought crucial improvements to patient access to health insurance, cancer patients still face serious challenges affording their care and using their insurance benefits.
Current federal requirements prohibit health insurance plans from denying coverage to individuals with pre-existing conditions like cancer. These are one of several important patient protections that must be part of any health care system that works for cancer patients.
